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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
reslizumab is effective in improving quality of life and asthma control in adolescent and adult 
patients with poorly controlled eosinophilic asthma.  
 
STUDY DESIGN: This is a systematic review of three randomized controlled trials, published in 
peer-reviewed journals from 2015 and 2016.  
 
DATA SOURCES: Three randomized, placebo-controlled, double-blind clinical trials comparing 
the effectiveness of reslizumab to a placebo in improving quality of life and asthma control. 
Articles were found using CINAL and PubMed databases. 
 
OUTCOMES MEASURED: Outcomes measured include quality of life, assessed using the 
Asthma Quality of Life Questionnaire (AQLQ), and asthma control, assessed using the Asthma 
Control Questionnaire-7 (ACQ-7). 
 
RESULTS: Bjermer et al. and Castro et al. showed significant improvement in quality of life in 
patients who received reslizumab compared to placebo. In Bjermer et al., 64% of patients 
receiving reslizumab achieved an improvement in their AQLQ score, compared to 48% for those 
receiving a placebo (p=0.0189). In Castro et al., 74% of patients receiving reslizumab had an 
improvement in their AQLQ score, compared to 65% of those receiving a placebo (p=0.03). 
Corren et al. showed a significant improvement in asthma control, with 71% of patients receiving 
reslizumab having improvement, compared to 57% of patients in the control group (p=0.01). 
 
CONCLUSION: Reslizumab is an effective treatment to improve quality of life and asthma 
control in patients with inadequately controlled eosinophilic asthma.  
 
KEY WORDS: Reslizumab, asthma  
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INTRODUCTION  
Asthma is a chronic inflammatory disease of the airways that is characterized by 
reversible obstruction, airway inflammation, bronchial hyperreactivity, and airway narrowing. 
Asthma is a common respiratory disease, affecting approximately 7.8% of the United States’ 
population.1 About 10% of these individuals have poorly controlled asthma.2 An estimated $56 
billion are spent annually for asthmatic patients.3 It is important to note that the subgroup of 
patients with poorly controlled asthma disproportionately contributes to these costs, likely due to 
increased exacerbations and hospitalizations. According to the CDC, the percentage of physician 
office visits for patients with asthma is 6.3% annually.4 The primary diagnosis of asthma 
accounts for an estimated two million emergency department visits annually.4  
It is known that asthma is caused by inflammation of the airways due to the infiltration of 
eosinophils, neutrophils, and T lymphocytes. This inflammation leads to airway edema and 
bronchial hyperreactivity that activates the immune system. Together, this leads to 
bronchoconstriction and limitation of airflow. There is a subgroup of asthmatic patients with an 
eosinophil-predominant inflammatory infiltrate in the airways and increased blood and sputum 
eosinophil levels.5 This subgroup is associated with poor treatment outcomes and increased risk 
of exacerbations.6 Eosinophils are regulated by interleukin-5 (IL-5) and require its signaling for 
growth and survival.5 This makes IL-5 inhibition a possible target for the treatment of 
eosinophilic asthma.  
Patients with asthma typically present with wheezing, dyspnea, cough, and other 
respiratory symptoms. A patient’s daily activity and quality of life may be limited depending on 
symptom severity. Standard treatments for asthma include short-acting agents that quickly treat 
airway narrowing, and long-term controller medications that aim to reduce airway inflammation. 
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Short-acting agents include inhaled short-acting beta-agonists (SABAs), such as albuterol, that 
work to cause bronchodilation and reverse airflow limitation. SABAs are required for all 
asthmatic patients for the immediate treatment of symptoms. Long-term controller medications 
include inhaled corticosteroids (ICS), long-acting beta-agonists, and leukotriene modifiers. Daily 
ICS therapy is currently the treatment of choice for persistent asthma. Systemic corticosteroids, 
supplemental oxygen, and other medications may be used in acute exacerbations.  
All of the medications previously listed are effective for managing symptoms or 
controlling asthma. However, they are not enough in cases of asthma with poor control, such as 
in the eosinophilic subgroup. Reslizumab (Cinqair) is a monoclonal antibody against IL-5 that 
has been approved by the FDA as an add-on therapy for poorly controlled eosinophilic asthma. 
By targeting IL-5, it works to decrease the number of eosinophils that cause airway 
inflammation. Therefore, the medication aims to improve asthma control and quality of life by 
targeting inflammation.  
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not reslizumab is 
effective in improving quality of life and asthma control in adolescent and adult patients with 
poorly controlled eosinophilic asthma. 
 
METHODS 
 Several criteria were used to search for and select studies for this EBM review. Each 
study included participants 12 years of age and older with inadequately controlled eosinophilic 
asthma. In each study, the intervention was a reslizumab 3.0 mg/kg infusion. Comparisons were 
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made between an experimental group receiving reslizumab infusions and a control group 
receiving a placebo infusion.  Outcomes measured included quality of life and asthma control. 
Types of studies included in this selective EBM review include three randomized, placebo-
controlled, double-blind clinical trials.  
 Articles were found using CINAL and PubMed databases, searching with key words 
“reslizumab and asthma.” The selected articles were published in the English language in peer 
reviewed journals from 2015-2016. Articles were chosen based on their relevance to the clinical 
question and if they included patient oriented outcomes. Inclusion criteria were randomized, 
placebo-controlled, double-blind clinical trials. Exclusion criteria were patients under the age of 
12 years old or who had well controlled asthma. Statistics reported in this review include relative 
benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), and p-
values. Table 1 demonstrates the demographics and characteristics of each study. 
Table 1: Demographics & Characteristics of included studies   
Study Type # 
Pts 
Age 
(years) 
Inclusion 
Criteria 
Exclusion Criteria W/D Intervention 
Bjermer5 
(2016) 
Double-
blind, 
placebo-
controlled 
RCT 
315 12-75 -ACQ-7 score 
 1.5. -Airway 
reversibility of 
12% or more 
after SABA 
administration.        
-Blood 
eosinophil 
count of 
400/L.  
-Receiving at 
least a 
medium dose 
ICS daily with 
or without 
another 
controller 
drug.  
-Confounding lung 
disorders/pulmonary 
conditions.  
-Hypereosinophilic 
syndrome.  
-Use of systemic 
corticosteroids 30 
days prior to 
screening.         
-Current smoker.  
-Use of systemic 
immunosuppressive 
or 
immunomodulating 
agents in the past 6 
months prior to 
screening.  
- Other clinically 
relevant 
50 Reslizumab 
infusion 3.0 
mg/kg q 4 
weeks x 16 
weeks 
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comorbidities with 
potential to interfere 
with the study 
schedule, 
procedures, or 
safety. 
Castro6 
(2015) 
Double-
blind, 
placebo-
controlled 
RCT 
489 12-75 -Same 
inclusion 
criteria as 
Bjermer 
(2016) in 
addition to the 
following:   
-At least one 
asthma 
exacerbation  
3 days within 
the past year 
before 
screening.  
-Same exclusion 
criteria as Bjermer 
(2016) in addition to 
the following:  
-Females could not 
be pregnant. 
-Prior use of 
reslizumab. 
-Requirement for 
treatment for an 
asthma exacerbation 
within 4 weeks of 
screening period. 
 
56 Reslizumab 
infusion 3.0 
mg/kg q 4 
weeks x 1 
year 
Corren8 
(2016) 
Double-
blind, 
placebo-
controlled 
RCT 
496 18-65 -Same 
inclusion 
criteria as 
Bjermer 
(2016) 
-Same exclusion 
criteria as Bjermer 
(2016)  
 
74 Reslizumab 
infusion 3.0 
mg/kg q 4 
weeks x 16 
weeks 
 
OUTCOMES MEASURED 
 Outcomes measured included quality of life and asthma control following the 
intervention. Bjermer et al. and Castro et al. used the Asthma Quality of Life Questionnaire 
(AQLQ) to assess quality of life in the participants at baseline and the end of the treatment 
period, which was at weeks 16 and 52, respectively.5-6 The AQLQ consists of 32 questions that 
assess asthma symptoms, activity limitation, emotions, and environmental stimuli.7 The 
participants are asked to evaluate how each area has impacted them in the previous two weeks, 
and rate each question on a 7-point scale; 1 meaning severely impaired, 7 meaning not impaired 
at all.7 The score for the AQLQ is an average of all of the responses. The creators of the AQLQ 
state that an improvement in the baseline score of  0.5 is the minimally important difference 
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(MID) that has clinical significance, because this improvement can warrant a change in a 
patient’s treatment plan.7 Both Bjermer et al. and Castro et al. used this MID, which allows for 
dichotomous data. Both studies used a stratified Cochran-Mantel-Haenszel test to identify the 
proportion of patients with a MID of  0.5-point improvement in their AQLQ score from 
baseline.5-6 
Corren et al. used the Asthma Control Questionnaire-7 (ACQ-7) to assess asthma control 
at baseline and 16 weeks, the end of the treatment period. 8 The participant uses a 7-point scale to 
answer questions related to night time awakenings, symptoms and severity, activity limitation, 
and rescue inhaler use that have occurred within the previous week.9 The scale ranges from 0 
(totally controlled asthma) to 6 (severely uncontrolled). The ACQ-7 also includes a FEV 
component measured by the researchers. The final ACQ-7 score is an average of all the 
responses. Asthma is considered to be well controlled with a score <1.5.5 Similar to the AQLQ, a 
change in baseline of  0.5-point decrease is the accepted MID for clinical significance.9 Corren 
et al. used this MID, allowing for dichotomous data.  
  
RESULTS 
All three of the studies included in this review compared adolescent and adult patients in 
an experimental group receiving a 3.0 mg/kg reslizumab infusion to a control group receiving a 
placebo infusion. The intervention was studied as an adjuvant therapy for patients already taking 
at least a medium-dose ICS with or without another controller medication. All patients had a 
blood eosinophil count of  400/L. A full set of inclusion and exclusion criteria can be found in 
Table 1 above. The first two studies assessed the efficacy of reslizumab in improving quality of 
life, while the third study assessed the efficacy of the medication to improve asthma control. 
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In the Bjermer et al. study, 315 patients were randomly allocated into experimental 
(n=106) and control (n=105) groups. 265 patients completed the trial, with 88 in the 
experimental group, and 85 in the placebo group. Another treatment group of 92 patients was 
included in the study, but this group received a different dose of reslizumab and was therefore 
excluded from this review. Patients were given an AQLQ at baseline and every 4 weeks until the 
end of the treatment period at 16 weeks. This review will focus on the AQLQ changes from 
baseline to week 16. Refer to Table 2 below for a summary of results from this study. Overall, 
64% of patients receiving reslizumab achieved a MID of  0.5-point improvement in their 
AQLQ score, compared to 48% for those receiving a placebo.5 This difference is statistically 
significant, with a p-value of 0.0189. Determining the number needed to treat (NNT) value is 
important to establish the clinical significance of the intervention. The NNT value in this study 
was 7, meaning that for every 7 patients with inadequately controlled eosinophilic asthma treated 
with reslizumab 3.0 mg/kg infusions every 4 weeks, 1 more patient will have an improvement in 
their quality of life compared to those receiving placebo.  
In the Castro et al. study, 489 patients were randomly assorted into experimental (n=245) 
and control (n=244) groups. 433 patients completed the trial, with 218 in the reslizumab group 
and 215 in the control group. It is important to note that this review focuses on the group of 
patients who completed Study 1 in the Castro et al. article, as two different studies are reported. 
Patients were given an AQLQ at baseline and weeks 16, 32, and 52. This review will focus on 
changes in AQLQ scores from baseline to week 52 at the end of the trial. Refer to Table 2 below 
for a summary of results from this study. A total of 74% of patients receiving reslizumab had a 
MID of  0.5-point improvement in their AQLQ score, compared to 65% of those receiving a 
placebo.6 This difference is statistically significant, with a p-value of 0.03. The NNT value in 
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this study was 12, meaning that for every 12 patients with inadequately controlled eosinophilic 
asthma treated with reslizumab 3.0 mg/kg infusions every 4 weeks, 1 more patient will have an 
improvement in their quality of life compared to those receiving placebo. 
Table 2: Comparison of improved AQLQ scores between reslizumab and placebo 
Study Control 
event rate 
(CER) 
Experiment 
event rate 
(EER) 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number 
needed to 
treat 
(NNT) 
P value 
Bjermer 
et al.5 
0.48 0.64 0.33 0.16 7 0.0189 
Castro et 
al.6 
0.65 0.74 0.14 0.09 12 0.03 
 
 In the Corren et al. study, 496 patients were randomized into experimental and control 
groups, with 398 receiving reslizumab and 98 receiving placebo. At the end of the 16-week 
treatment period, 422 patients completed the trial, with 340 enrolled in the experimental group 
and 82 in the control group. ACQ-7 scores were compared from baseline and 16 weeks. Refer to 
Table 3 below for a summary of results. 71% of patients receiving reslizumab had an 
improvement in their asthma control with a  0.5-point decrease from baseline, compared to 57% 
of patients in the control group.8 This difference is statistically significant, with a p-value of 
0.01. The NNT value in this study was 8, meaning that for every 8 patients with poorly 
controlled asthma treated with reslizumab 3.0 mg/kg infusions q 4 weeks, 1 more patient will 
have an improvement in their asthma control compared to those receiving placebo. 
Table 3: Comparison of improved ACQ-7 scores between reslizumab and placebo (Corren 
et al.8) 
Control 
event rate 
(CER) 
Experiment 
event rate 
(EER) 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number 
needed to 
treat (NNT) 
P value 
0.57 0.71 0.25 0.14 8 0.01 
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DISCUSSION 
Reslizumab was recently approved by the FDA as an adjunctive controller medication for 
the management of inadequately controlled eosinophilic asthma. As mentioned previously, it was 
studied in patients taking at least a medium-dose ICS with or without another controller 
medication. It does not have any other treatment indications and should not be used for the 
treatment of acute symptoms or asthma exacerbations. It is approved for a monthly intravenous 
dosing of 3.0 mg/kg.10 Although this medication cannot be taken by the patient at home, it is still 
feasible because they only have to get it once per month, and it only takes 20-50 minutes to 
infuse.10 Adverse effects reported for reslizumab include headache, URI, nausea and vomiting, 
allergic rhinitis, back pain, sinusitis, UTI, dyspnea, dizziness, and oropharyngeal pain.10 It is 
important to note that reslizumab has a Black Box warning for anaphylaxis.10 The only 
contraindication is an allergy to the medication.  
The first two studies showed that those treated with reslizumab had significant 
improvement in AQLQ scores, and the third study showed significant improvement in the ACQ-
7 score for those treated with reslizumab compared to placebo. The treatment effects of 
reslizumab in improving quality of life and asthma control were large based on the small NNT 
values listed above, considering this medication is an adjunctive therapy and the drug is 
relatively tolerable. Since the treatment effects are large, reslizumab holds a justified clinical 
importance as an adjuvant treatment for inadequately controlled eosinophilic asthma.  
While data show that there was a statistically significant number of patients who had a 
MID of  0.5-point decrease in their ACQ-7 score (i.e. improvement in asthma control), it is 
possible that their asthma was still not controlled. Adequately controlled asthma correlates with 
an ACQ-7 score of <1.5.5 It is possible that some patients, while achieving a MID in 
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improvement, still had an ACQ-7 score 1.5 indicating they still had inadequately controlled 
asthma after receiving reslizumab. While an improvement in their score is certainly a step in the 
right direction, it may not be enough to justify the use of this medication to convert a patient’s 
status to well controlled asthma. Since the clinical question posed in this review only investigates 
an improvement in asthma control, this would be an area of interest for further study.  
One limitation to the studies is the route of administration, but unfortunately this cannot 
be avoided. Researchers discuss that receiving an IV infusion may cause patients to perceive 
stronger treatment effects due to the route of administration, so this could have affected the 
outcomes measured.6 However, the intervention was compared to a placebo infusion and had a 
statistically significant difference in outcomes. Patient self-report and honesty on the AQLQ and 
ACQ-7 could have affected outcomes as well. The questions covered a span of the previous 1 or 
2 weeks, and patients may have an error in their memory that affected their responses and 
therefore the outcomes measured.  Another limitation explained by the original researchers is 
that using a MID of  0.5-point improvement in AQLQ scores is not a valid measure to assess 
outcomes for groups of patients when an adjuvant therapy is added to their current ICS regimen.5 
While not explicitly mentioned by Corren et al., the validity of the MID for the ACQ-7 score 
may be questionable as well. Further studies are warranted to determine the validity of using a 
MID for both the AQLQ and ACQ-7 when adding a therapy to an ICS regimen.  
 
CONCLUSION 
Reslizumab is an effective treatment to improve both quality of life and asthma control in 
a subgroup of patients with poorly controlled eosinophilic asthma. Future study is warranted to 
evaluate if a significant number of patients achieve a MID in improvement in their ACQ-7 score 
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in addition to an ACQ-7 score of <1.5, indicating well controlled asthma. Reslizumab should not 
be indicated as monotherapy in these patients, but considered as an add-on treatment in those 
who are not well controlled with the use of a medium-dose ICS, as this was the population in 
each study. 
 References 
 
1.  Most Recent Asthma Data. Centers for Disease Control and Prevention. 
https://www.cdc.gov/asthma/most_recent_data.htm. Updated June 2017. Accessed October 5, 
2017.  
2. Walford HH and Doherty TA. Diagnosis and management of eosinophilic asthma: A US 
perspective. J Asthma Allergy. 2014;7:53-65. doi: 10.2147/JAA.S39119. 
3. Vital Signs: Asthma in the US. Centers for Disease Control and Prevention. 
https://www.cdc.gov/vitalsigns/asthma/index.html. Published May 2011. Accessed October 5, 
2017.  
4. National Center for Health Statistics. Centers for Disease Control and Prevention. 
https://www.cdc.gov/nchs/fastats/asthma.htm. Updated March 31, 2017. Accessed October 5, 
2017.  
5. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for 
inadequately controlled asthma with elevated blood eosinophil levels: A randomized phase 3 
study. Chest. 2016;150(4):789-798. doi: 10.1016/j.chest.2016.03.032. 
6. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, 
Maspero JF, O’Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated 
blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, 
placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366. doi: 10.1016/S2213-
2600(15)00042-9. 
7. Asthma Quality of Life Questionnaire. QOL Technologies Web site. 
http://www.qoltech.co.uk/aqlq.html. Accessed December 10, 2017.  
8. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients 
with poorly controlled asthma: Effects across a broad range of eosinophil counts. Chest. 
2016;150(4):799-810. doi: 10.1016/j.chest.2016.03.018. 
9. Asthma Control Questionnaire. QOL Technologies Web site. 
http://www.qoltech.co.uk/acq.html. Accessed December 10, 2017.  
10. Reslizumab (AHFS Essentials Adult and Pediatric). Lexicomp Online. 
http://online.lexi.com.ezproxy.pcom.edu:2048/lco/action/doc/retrieve/docid/essential_ashp/6332
778. Published March 22, 2017. Accessed December 13, 2017. 
